[go: up one dir, main page]

MX2010004292A - Producto de dispersion solida que contiene un compuesto a base de n-aril urea. - Google Patents

Producto de dispersion solida que contiene un compuesto a base de n-aril urea.

Info

Publication number
MX2010004292A
MX2010004292A MX2010004292A MX2010004292A MX2010004292A MX 2010004292 A MX2010004292 A MX 2010004292A MX 2010004292 A MX2010004292 A MX 2010004292A MX 2010004292 A MX2010004292 A MX 2010004292A MX 2010004292 A MX2010004292 A MX 2010004292A
Authority
MX
Mexico
Prior art keywords
solid dispersion
dispersion product
based compound
product containing
aryl urea
Prior art date
Application number
MX2010004292A
Other languages
English (en)
Inventor
Rudolf Schroeder
Tanja Heitermann
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MX2010004292A publication Critical patent/MX2010004292A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un producto que comprende al menos un agente farmacéuticamente activo a base de N-aril urea o un agente de estructura relacionada que es obtenido mediante a) la preparación de una mezcla líquida que contiene el al menos un agente activo, el al menos un agente formador de matriz aceptable para uso farmacéutico, el al menos un agente tensoactivo aceptable para uso farmacéutico y el al menos un solvente, y b) la eliminación del o de los solventes de la mezcla líquida para obtener el producto de dispersión sólida.
MX2010004292A 2007-10-19 2008-10-17 Producto de dispersion solida que contiene un compuesto a base de n-aril urea. MX2010004292A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99961307P 2007-10-19 2007-10-19
PCT/EP2008/064073 WO2009050289A2 (en) 2007-10-19 2008-10-17 Solid dispersion product containing n-aryl urea-based compound

Publications (1)

Publication Number Publication Date
MX2010004292A true MX2010004292A (es) 2010-08-02

Family

ID=40089072

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004292A MX2010004292A (es) 2007-10-19 2008-10-17 Producto de dispersion solida que contiene un compuesto a base de n-aril urea.

Country Status (23)

Country Link
US (1) US20090143423A1 (es)
EP (1) EP2197426A2 (es)
JP (1) JP2011500647A (es)
KR (1) KR20100090689A (es)
CN (1) CN101827585A (es)
AR (1) AR068916A1 (es)
AU (1) AU2008313620A1 (es)
BR (1) BRPI0818339A2 (es)
CA (1) CA2699335A1 (es)
CL (1) CL2008003092A1 (es)
CO (1) CO6270303A2 (es)
CR (1) CR11441A (es)
DO (1) DOP2010000114A (es)
EC (1) ECSP10010184A (es)
GT (1) GT201000095A (es)
MX (1) MX2010004292A (es)
PE (1) PE20091041A1 (es)
RU (1) RU2010119924A (es)
TW (1) TW200922549A (es)
UA (1) UA100866C2 (es)
UY (1) UY31406A1 (es)
WO (1) WO2009050289A2 (es)
ZA (1) ZA201002130B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505907A (ja) * 2008-10-17 2012-03-08 アボット・ラボラトリーズ Ｔｒｐｖ１拮抗薬
MX2011004090A (es) * 2008-10-17 2011-05-31 Abbott Lab Antagonistas trpv1.
US20100210682A1 (en) * 2009-02-19 2010-08-19 Abbott Laboratories Repeated Dosing of TRPV1 Antagonists
WO2011032860A1 (de) * 2009-09-18 2011-03-24 Basf Se Verfahren zur herstellung von zubereitungen von in wasser schwerlöslichen substanzen
MX341873B (es) 2010-12-23 2016-09-06 Abbvie Deutschland Formulaciones solidas de retardo basadas en dispersiones solidas.
ES2632979T3 (es) 2011-01-10 2017-09-18 Celgene Corporation Formas de dosificación oral de {2-[(1S)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-3-oxo-2,3-dihidro-1H-isoindol-4-il}-amida de ácido ciclopropanocarboxílico
US20130172239A1 (en) * 2011-12-29 2013-07-04 Abbvie Inc. Solid compositions
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
PL2950786T3 (pl) 2013-01-31 2020-05-18 Gilead Pharmasset Llc Formulacja skojarzona dwóch związków przeciwwirusowych
JP6130585B2 (ja) 2013-03-15 2017-05-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 無定形状態のｈｃｖ阻害薬の固体経口投薬製剤
WO2015001012A1 (de) 2013-07-03 2015-01-08 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches system mit elektronischem bauteil
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
EP3145503A1 (en) 2014-05-20 2017-03-29 LTS Lohmann Therapie-Systeme AG Method for adjusting the release of active agent in a transdermal delivery system
CA2948221C (en) 2014-05-20 2022-11-22 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
CA2948220C (en) * 2014-05-20 2023-06-20 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
CA2987867C (en) 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
US12186314B2 (en) * 2015-12-22 2025-01-07 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia
EP3873443A4 (en) 2018-10-30 2022-07-27 Peloton Therapeutics, Inc. SOLID DISPERSIONS AND PHARMACEUTICAL COMPOSITIONS WITH A SUBSTITUTED INDAN AND PROCESSES FOR THEIR PREPARATION AND USE THEREOF
WO2021039023A1 (ja) 2019-08-23 2021-03-04 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の製造方法
MX2022002017A (es) 2019-08-23 2022-03-11 Mochida Pharm Co Ltd Metodo para producir derivado de heterociclideno acetamida.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362878A (en) * 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
CA2134359C (en) * 1992-05-28 1997-07-01 Ernest S. Hamanaka New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
JP2002520377A (ja) * 1998-07-14 2002-07-09 イーエム インダストリーズ インコーポレイテッド ミクロ分散薬物送達システム
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
EP1765283A4 (en) * 2004-06-08 2012-11-28 Vertex Pharma PHARMACEUTICAL COMPOSITIONS
US20060078617A1 (en) * 2004-08-27 2006-04-13 Fritz Schueckler Pharmaceutical compositions for the treatment of cancer
MX2007012947A (es) * 2005-04-18 2008-04-09 Rubicon Res Pvt Ltd Composiciones biomejoradas.
KR100715355B1 (ko) * 2005-09-30 2007-05-07 주식회사유한양행 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
EP1959926A1 (en) * 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
US7745448B2 (en) * 2005-12-28 2010-06-29 Abbott Laboratories Inc. Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate
CN103735515A (zh) * 2006-02-09 2014-04-23 默沙东公司 Cetp抑制剂的聚合物制剂

Also Published As

Publication number Publication date
EP2197426A2 (en) 2010-06-23
UY31406A1 (es) 2009-05-29
JP2011500647A (ja) 2011-01-06
TW200922549A (en) 2009-06-01
CA2699335A1 (en) 2009-04-23
KR20100090689A (ko) 2010-08-16
CR11441A (es) 2010-10-25
WO2009050289A2 (en) 2009-04-23
CO6270303A2 (es) 2011-04-20
WO2009050289A3 (en) 2010-03-25
ZA201002130B (en) 2011-11-30
BRPI0818339A2 (pt) 2015-04-22
GT201000095A (es) 2012-04-03
AU2008313620A1 (en) 2009-04-23
RU2010119924A (ru) 2011-11-27
UA100866C2 (ru) 2013-02-11
DOP2010000114A (es) 2010-05-15
CL2008003092A1 (es) 2009-11-27
CN101827585A (zh) 2010-09-08
US20090143423A1 (en) 2009-06-04
PE20091041A1 (es) 2009-08-22
AR068916A1 (es) 2009-12-16
ECSP10010184A (es) 2010-06-29

Similar Documents

Publication Publication Date Title
MX2010004292A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea.
MX2010004291A (es) Producto de dispersion solida de farmacos basados en n-aril urea.
WO2010015567A3 (en) Controlled release formulations using intelligent polymers
CR9292A (es) Comprimidos con dispersion mejorada de la sustancia farmacologica
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
WO2007125103A3 (en) Benzamide glucokinase activators
WO2007086078A3 (en) Novel pharmaceutical compositions and process of preparation thereof
WO2009135179A3 (en) The use of solid carrier particles to improve the processability of a pharmaceutical agent
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
PL2046292T3 (pl) Preparaty eterów benzymidazolilo-pirydylowych
WO2008073138A3 (en) Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors
WO2012066488A3 (en) Bridged spiro[2.4]heptane ester derivatives
WO2010017433A3 (en) Use of sucralose as a granulating agent
WO2008103847A3 (en) Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
EP2011544A3 (en) Structured Depilatory Compositions
WO2011103610A3 (de) Pflanzenschutzmittel
WO2014062838A3 (en) Pkm2 modulators and methods for their use
WO2009060952A1 (ja) 新規製剤
WO2013093931A3 (en) Novel prodrugs of phenolic drugs
MX363699B (es) Producto de comicronizacion que comprende acetato de ulipristal.
WO2009097973A3 (de) Imidazopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
WO2006110810A3 (en) Polymorphs of 3-o-(3',3'-dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine
WO2010058104A3 (fr) Compositions pharmaceutiques utilisant l'inuline comme excipient de granulation
WO2008032208A3 (en) Extended release formulation of an antiepileptic agent
WO2007143506A3 (en) Substituted benzimidazole thiophene benzyl ether compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal